Get the Stockscreener App
42.00
1.06%
-0.45
Vera Therapeutics Inc stock is traded at $42.00, with a volume of 2.85M.
It is down -1.06% in the last 24 hours and up +32.83% over the past month.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
See More
Previous Close:
$42.45
Open:
$42.15
24h Volume:
2.85M
Relative Volume:
1.89
Market Cap:
$3.01B
Revenue:
-
Net Income/Loss:
$-368.95M
P/E Ratio:
-7.574
EPS:
-5.5453
Net Cash Flow:
$-293.81M
1W Performance:
+1.94%
1M Performance:
+32.83%
6M Performance:
-13.78%
1Y Performance:
+72.48%
1-Day Range:
$38.86
$42.15
1-Week Range:
$38.86
$44.60
52-Week Range:
$19.07
$56.05
Vera Therapeutics Inc Stock (VERA) Company Profile
Name
Vera Therapeutics Inc
Sector
Industry
Phone
650-770-0077
Address
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Compare VERA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
42.00 | 3.01B | 0 | -368.95M | -293.81M | -5.5453 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-16-25 | Initiated | BofA Securities | Buy |
| Aug-04-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-05-25 | Resumed | H.C. Wainwright | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Jan-28-25 | Initiated | Goldman | Buy |
| Nov-21-24 | Initiated | Wells Fargo | Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jan-25-24 | Initiated | Oppenheimer | Outperform |
| Jan-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-18-23 | Initiated | Raymond James | Outperform |
| Nov-10-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-16-23 | Initiated | Guggenheim | Buy |
| Jan-04-23 | Downgrade | Jefferies | Buy → Hold |
| Jan-04-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-12-22 | Initiated | JP Morgan | Overweight |
| May-02-22 | Initiated | H.C. Wainwright | Buy |
| Apr-19-22 | Initiated | Wedbush | Outperform |
View All
Vera Therapeutics Inc Stock (VERA) Latest News
Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch - Yahoo Finance
New Vera Therapeutics employees receive $40.13 stock options in inducement plan - Stock Titan
Is FDA Accelerated Approval Of TRUTAKNA Transforming The Investment Case For Vera Therapeutics (VERA)? - Yahoo Finance
Vera Therapeutics (VERA) Wins FDA Approval For TRUTAKNA, Is The Stock Fully Priced? - Sahm
(VERA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Vera Therapeutics (VERA) Could Be 92% Below Fair Value After FDA Approval - Yahoo Finance
Rx Rundown: Vertex Pharmaceuticals, Real Chemistry, Vera Therapeutics and more - Medical Marketing and Media
Vera Therapeutics (VERA) Stock Looks Fully Valued After Its 185% Run - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Form 4 Vera Therapeutics Inc For: 9 July By Investing.com - Investing.com Nigeria
Vera Therapeutics CEO Fordyce Marshall sells shares worth $1.96 million By Investing.com - Investing.com Nigeria
Vera Therapeutics CEO Fordyce Marshall sells shares worth $1.96 million - Investing.com
Vera Therapeutics (VERA) CEO preplanned sale of 46,250 shares reported - Stock Titan
Vera Therapeutics: A Crowded IgAN Market Leaves No Room For A Premium (Downgrade) - Seeking Alpha
Vera Therapeutics names Nancy Boman as chief regulatory officer By Investing.com - Investing.com India
Vera Therapeutics, Inc. Files Form 8-K with SEC: Key Company and Stock Information for July 2026 - Minichart
Vera Therapeutics Announces New Chief Regulatory Officer - TipRanks
Vera Therapeutics names Nancy Boman as chief regulatory officer - Investing.com
Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner - The Manila Times
Executive shakeup at Vera Therapeutics (VERA) as new Chief Regulatory Officer named - Stock Titan
Vera Therapeutics Announces Appointment of Nancy Boman as - GlobeNewswire
Vera Therapeutics’ First-in-Class Kidney Disease Drug Lands Speedy FDA Approval - MedCity News
Vera Therapeutics (VERA) Q4 2025 earnings summary - Quartr
Vera Therapeutics (VERA) Q1 2026 earnings summary - Quartr
Vera Therapeutics (VERA) 2024 Cantor Fitzgerald Global Healthcare Conference Summary - Quartr
Vera Therapeutics (VERA) TD Cowen 46th Annual Health Care Conference Summary - Quartr
Vera Therapeutics' Trutakna Pricing Tops Expectations, Wedbush Says - Moomoo
Cantor Fitzgerald reiterates Vera Therapeutics stock rating on IgAN approval By Investing.com - Investing.com South Africa
Vera Therapeutics stock price target raised to $125 by H.C. Wainwright on FDA approval By Investing.com - Investing.com South Africa
Guggenheim raises Vera Therapeutics stock price target on FDA approval By Investing.com - Investing.com India
FDA grants accelerated approval to Vera Therapeutics' Trutakna - qz.com
US FDA approves Vera's kidney disease drug - Reuters
Vera Therapeutics (VERA) Proxy filing Summary - Quartr
Cantor Fitzgerald reiterates Vera Therapeutics stock rating on IgAN approval - Investing.com
A Quick Look at Today's Ratings for Vera Therapeutics(VERA.US), With a Forecast Between $47 to $125 - Moomoo
Vera Therapeutics stock price target raised to $125 by H.C. Wainwright on FDA approval - Investing.com South Africa
Vera Therapeutics wins FDA accelerated approval for Trutakna - The Pharma Letter
TRUTAKNA’s Dual-Pathway FDA Nod Could Be A Game Changer For Vera Therapeutics (VERA) - Sahm
Vera Therapeutics (VERA) FDA announcement Summary - Quartr
Vera Therapeutics (NASDAQ:VERA) stock up; Trutakna approval shifts attention to Q3 kidney data - TechStock²
Vera Therapeutics wins first FDA approval with kidney disease drug - The Business Journals
VERA Stock Surges After Drug To Treat Rare Kidney Disease Gets FDA Approval – Retail Sees The Move As Catalyst For Vera Therapeutics - Stocktwits
Why Is Vera Therapeutics Stock Gaining Tuesday? - Benzinga
VERA Stock Holds Gains As CEO Trims Stake In Form 4 Sale - StocksToTrade
Vera Therapeutics gains FDA nod for TRUTAKNA launch - TipRanks
Vera Therapeutics secures FDA approval for TRUTAKNA - grafa.com
Vera gains after FDA nod for kidney disease therapy - Seeking Alpha
Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy - The Manila Times
FDA grants accelerated approval to Vera Therapeutics (NASDAQ: VERA) drug TRUTAKNA - Stock Titan
FDA approves Vera Therapeutics kidney disease treatment - STAT
Vera Therapeutics Receives FDA Accelerated Approval for - GlobeNewswire
Vera Therapeutics Inc Stock (VERA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vera Therapeutics Inc Stock (VERA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Fordyce Marshall | PRESIDENT AND CEO |
Jun 23 '26 |
Sale |
37.93 |
18,500 |
701,769 |
198,244 |
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):